Literature DB >> 12390546

Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.

Jon Warren1.   

Abstract

This current supplementary and systematic survey of 237 preclinical AIDS vaccine challenge/protection studies in nonhuman primates enumerates and broadly describes the recent status of different vaccine strategies in macaque and chimpanzee experimental models. Published studies since the previous survey were compiled and categorized by their vaccine types, challenge parameters, and challenge results. These models have supportively verified that some prophylactic vaccine approaches, though rarely preventing infection (which is observed in these models with some passively administered antibody-based vaccines), can control to some degree primate lentivirus replication and disease development, and this is encouraging because it places more potentially effective immunogens on the precipice for early clinical studies. Many of these promising approaches may benefit from more testing in mucosal challenge models, and resources will be needed to follow more of these partially protected vaccinees for longer periods.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390546     DOI: 10.1034/j.1600-0684.2002.02010.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  9 in total

1.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge.

Authors:  Santhi Gorantla; Kathlyn Santos; Vakara Meyer; Stephen Dewhurst; William J Bowers; Howard J Federoff; Howard E Gendelman; Larisa Poluektova
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.

Authors:  Feng Li; Jodi K Craigo; Laryssa Howe; Jonathan D Steckbeck; Sheila Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.

Authors:  Kaifan Dai; Salar N Khan; Yimeng Wang; Linling He; Javier Guenaga; Jidnyasa Ingale; Christopher Sundling; Sijy O'Dell; Krisha McKee; Ganesh Phad; Martin Corcoran; Richard Wilson; John R Mascola; Jiang Zhu; Yuxing Li; Gunilla B Karlsson Hedestam; Richard T Wyatt
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

6.  Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.

Authors:  Grant D Trobridge; Robert A Wu; Brian C Beard; Sum Ying Chiu; Nina M Muñoz; Dorothee von Laer; John J Rossi; Hans-Peter Kiem
Journal:  PLoS One       Date:  2009-11-02       Impact factor: 3.240

7.  HIV-1 Vaccine Trials: Evolving Concepts and Designs.

Authors:  Missa P Sanou; Anne S De Groot; Michael Murphey-Corb; Jay A Levy; Janet K Yamamoto
Journal:  Open AIDS J       Date:  2012-11-30

8.  Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo.

Authors:  H-P Kiem; R A Wu; G Sun; D von Laer; J J Rossi; G D Trobridge
Journal:  Gene Ther       Date:  2009-09-10       Impact factor: 5.250

9.  The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.

Authors: 
Journal:  PLoS Med       Date:  2005-01-18       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.